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Multiple autoimmune syndrome (MAS) is a 
condition in which patients have at least three 
distinct autoimmune conditions. The defi nition 
of MAS is based on 91 reported cases of such 
associations in the literature. A review of the 
literature and cluster analysis of MAS disclosed 
systemic lupus erythematosus (SLE), Sjögren’s 
syndrome, and autoimmune thyroid disease (AITD) 
as the “chaperones” of autoimmune diseases. This 
entity was described by Humbert and Dupond in 
1988 as a syndrome consisting of the presence 
of three or more autoimmune diseases in a single 
patient. While describing the syndrome, their 
observations led them to a rough classifi cation of 
clusters based on the co-occurrence of autoimmune 
disease, which they identifi ed as types one through 
three.1 In MAS-1, the authors grouped myasthenia 
gravis, thymoma, dermatopolymyositis, and 
autoimmune myocarditis together. In MAS-2, they 
grouped Sjögren’s syndrome, rheumatoid arthritis, 
primary biliary cirrhosis, systemic sclerosis (SSc), 
and AITD.  MAS-3 consists of AITD, myasthenia 
gravis and/or thymoma, Sjögren’s syndrome, 
pernicious anemia, idiopathic thrombocytopenic 
purpura, Addison’s disese, type 1 diabetes, vitiligo, 
autoimmune hemolytic anemia, and SLE.1,2,3 The 
importance of this concept is the probability that 
having three autoimmune diseases simultaneously in 
one patient goes beyond epidemiological inferences 
or statistical chance. Disorders of autoimmune 
pathogenesis occur with increased frequency in 
patients with a history of another autoimmune 
disease. The tendency to develop another disease 
occurs in about 25% of these patients.3,4 
We report a case in which the presence of 
Graves’ disease/AITD, SLE, vasculitis, and SSc 
with pulmonary hypertension and Raynaud’s 
phenomenon in one patient.
CASE REPORT
A 30-year-old Indonesian woman, was fi rst 
diagnosed with Graves’ disease when she was 17 
years old based on the presence of hyperthyroidism, 
diffuse goiter, and specifi c laboratory fi ndings. 
She was an outpatient of the endocrinology clinic 
at Cipto Mangunkusumo General Hospital and 
treated with propylthiouracil 100 mg t.i.d and 
propranolol 10 mg t.i.d. For the past 3 years, she 
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had been complaining of photosensitivity, hair loss, 
recurrent oral ulcer, and bilateral pretibial edema. 
She also had a history of a focal neurological 
defi cit in the form of involuntary movement. She 
underwent a renal biopsy on June 2007 and was 
given the diagnoses of SLE with lupus nephritis 
and lupus cerebritis. She was treated with steroid 
and mycophenolate mofetil. For the past 6 months, 
she had been presenting clinical characteristic 
of Raynaud’s phenomenon and scleroderma. 
The symptoms became worse and her fi ngers 
developed gangrene. She had been hospitalized for 
two months, underwent many examinations and 
was given the diagnoses of SSc with pulmonary 
artery hypertension, Raynaud’s phenomenon, and 
vasculitis.
The results of her physical examination were 
as follows: she was compos mentis, blood pressure 
was 120/80 mmHg, pulse rate was 88 beats/minute, 
respiratory rate was 20 breaths/minute, and body 
temperature was 36.7°C. On head examination, we 
found lupus hair, mask-like face, moon face with 
salt-and-pepper appearance, no lid retraction, no 
proptosis, no trismus, no pale conjunctiva, and no 
oral ulcers. There was diffuse goiter on her neck. 
On heart auscultation we found loud pulmonary 
valve sound without audible murmur or pericardial 
friction rub. On the extremities, there were 
vasculitis in both arms and both legs, Raynaud’s 
phenomenon and gangrene of fi nger II, III, and IV 
of the left hand, and   thickening of the skin from 
fi ngers to trunk (shoulder, back, and neck). We also 
found peripheral neuropathy and moist hand. We 
did not fi nd any arthritis, tremor, or edema.  
Figure 1   (A) Lupus hair; “salt-and-pepper” 
appearance of the face. (B) Vasculitis of the legs.
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Figure 2   Raynaud’s phenomenon and vasculitis of the left hand.
Laboratory studies disclosed the following values: 
hemoglobin 12.9 g/dL, hematocrit 38.5%, leukocyte count 
4.31 × 103/mm3, platelet count 295 × 103/mm3, erythrocyte 
sedimentation rate 15 mm/hr, blood glucose 83 mg/dL, blood 
urea nitrogen 33 mg/dL, serum creatinine 0.5 mg/dL, Na 137 
mEq/L, K 3.38 mEq/L, aspartate aminotransferase 61 IU/
L, alanine aminotransferase 34 IU/L, total protein 7.2 U/L, 
albumin 3.71 U/L, globulin 3.49 U/L, total cholesterol 161 
mg/dL, low-density lipoprotein cholesterol 63 mg/dL, high-
density lipoprotein cholesterol 71 mg/dL, fi brinogen 268 mg/
dL, D-dimer 1800 ng/mL, activated partial thromboplastin 
time 0.7 times control, prothrombin time 0.7 times control. 
The urinalysis showed proteinuria (+1), hematuria, and 
sediment of erythrocyte and leukocyte. The creatinine 
clearance test was 137.23 mL/min, and the total urine protein 
was 65 mg/24 hours (with a history of total urine protein of 
800 mg/24 hours). Thyroid function test revealed as follows: 
stimulated thyroid-stimulating hormone (TSHs) 0.010 IU/mL 
(normal value 0.270-4.200), total T4 13.64 mg/dL (normal 
value 5.100-14.100), total T3 1.640 ng/mL (normal value 
0.800-2.000), free T4 3.07 ng/dL (normal value 0.70-1.48), 
thyrotropine receptor antibodies (TRAb) 2.5 mg/dL (positive). 
Antinuclear antibodies (ANA) profi le was positive for anti–
SS-A (+), anti–SS-B (+), anti–Scl-70 (+++), and anti–Rib-
P protein (+++), with nucleolar pattern. Anticardiolipin 
antibodies (ACA) IgM was 3.5 (negative), ACA IgG was 2.4 
(negative), IgG and IgM of 2-glycoprotein I was negative, 
and. Complement component (C)3 was 56.50 mg/dL (normal 
value 90-180), C4 was 20.80 mg/dL (normal value 10-40). 
Anti–double-stranded DNA (anti-dsDNA) was positive by 
enzyme-linked immunosorbent assay method. 
The chest radiograph was normal; there was no infi ltration. 
Echocardiography showed ejection fraction 69%, normal left 
ventricular systolic and diastolic function, and pulmonary 
artery hypertension. Skin biopsy confi rmed SLE-related 
vasculitis. Thyroid scanning showed diffuse goiter with high 
radioiodine uptake. Renal biopsy confi rmed nephritis lupus 
class I. Arteriography showed total occlusion of fi nger II, III, 
and IV of the left hand. Cerebral magnetic resonance imaging 
was normal. Electroencephalography (EEG) showed episode 
of epileptiform activity on the left frontotemporal area. Ankle-
brachial index (ABI) was 0.84/0.91.
The diagnoses were fi nally established: type 3 MAS 
consisting of Graves’ disease/AITD, SLE and vasculitis, 
SSc with pulmonary artery hypertension and Raynaud’s 
phenomenon. The patient was treated with warfarin 2 mg 
with dose titration to international normalized ratio target of 
2.5-3.5 (after intravenous heparin), acetyl salicylic acid 80 
mg q.d., nifedipine 10 mg b.i.d., and cilostazol 50 mg b.i.d. 
for Raynaud’s phenomenon; beraprost 3 × 20 mcg t.i.d. for 
pulmonary hypertension; cefotaxime 1 g t.i.d., and bacitracin 
cream; methylprednisolone pulse dose 125 mg for 3 hour, 
tapered down to 16 mg t.i.d., mycophenolate mofetil 500 
mg b.i.d. for vasculitis and SLE; thiamazole 40 mg q.d. and 
propranolol 10 mg t.i.d. for AITD (Graves’ disease); calcium 
hydrogen phosphate 500 mg and cholecalciferol 133 IU 1 
tablet t.i.d; diclofenac sodium 25 mg b.i.d., omeprazole 20 mg 
b.i.d., cyclophosphamide 500 mg i.v. (Euro-Lupus Nephritis 
protocol) 3 times per 2 weeks followed by 6 times per 4 
weeks.
The clinical response to all treatments were remarkably 
good; the thickening of the skin and gangrene of the fi ngers 
were resolved in the fi fth month of therapy.
 
Figure 3   Fingers of the left hand after 5 months therapy.
DISCUSSION 
Disorders of autoimmune pathogenesis occur with increased 
frequency in patients with history of another autoimmune 
disease. The tendency to develop another disease occurs 
in about 25% of these patients.3,4 Multiple autoimmune 
syndrome can be classifi ed into three groups according to 
the prevalence of their associations with one another. For 
these groups, HLA-B8 and/or -DR3 or -DR5 seems to be 
an important factor.2,3,4 This classifi cation helps to detect a 
new condition liable to appear in a patient who has had two 
previous autoimmune diseases. It provides a basis for analysis 
of the pathophysiological mechanisms of autoimmunity. 
In MAS, patients often have at least one dermatological 
condition, usually vitiligo or alopecia areata. In many cases 
of MAS reported in the medical literature, vitiligo is the fi rst 
autoimmune disease to be diagnosed. In these cases, vitiligo is 
usually bilateral and symmetrical, and in most cases of vitiligo 
that occurred in MAS, AITD was also present.5,6,7
Familial or genetic, infectious, immunologic, and 
psychological factors have all been implicated in the 
development of MAS. Cytomegalovirus, for instance, is shown 
to cause the development of multiple autoantibodies, and 
certain autoantibodies are found in disorders affecting multiple 
organs. 2,4,8,9 Multiple autoantibodies can be found in a patient 
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and some of the specifi c mono- or polyclonal autoantibodies 
may be multiple organ-reactive. In conclusion, the presence of 
one autoimmune disease should alert one to watch for another 
one. The occurrence of multiple autoimmune phenomena in 
these cases indicates the need for continued surveillance for 
the development of new autoimmune disease in predisposed 
patients.2,3,4,9
MAS-3 consisted of AITD, myasthenia gravis and/or 
thymoma, Sjögren’s syndrome, pernicious anemia, idiopathic 
thrombocytopenic purpura, Addison’s disease, type 1 diabetes 
mellitus, vitiligo, autoimmune hemolytic anemia, and 
SLE.3,6,7,10,11 Our case was defi ned as the type 3 MAS with 
AITD/Graves’ disease, diffuse-type SSc, and SLE. 
The diagnosis of AITD/Graves’ disease was based on the 
clinical characteristics (hyperthyroidism, diffuse goiter with 
high radioiodine uptake on thyroid scanning) and specifi c 
laboratory results (positive TRAb (2.5 mg/dL), low level of 
TSHs (0.010 IU/mL), and high level of free T4 (3.07 mg/
dL)).
Graves’ disease is an AITD characterized clinically by 
the presence of hyperthyroidism, diffuse goiter, and in some 
patients, ophthalmopathy and dermopathy. Graves’ disease is 
caused by circulating antibodies directed against TRAb that 
activate the thyrotropin receptor causing thyrotoxicosis. The 
cause of Graves’ ophthalmopathy and dermopathy is still 
unknown, but a cross-reaction between thyroidal and orbital 
and/or connective tissue antigens has been postulated. In this 
case, it has also been documented for the diagnosis of Graves’ 
disease, and gave a good response to thiamazole. In several 
case reports, treatment of one autoimmune disease may result 
in the emergence of yet another disease such as SLE or systemic 
sclerosis. In our patient, methylprednisolone combined with 
intravenous cyclophosphamide for the treatment of SLE 
(cerebral and renal involvement) was associated with the 
emergence of Raynaud’s phenomenon with digital gangrene 
as well as SSc. The term “kaleidoscope of autoimmunity” has 
recently been used to describe the shift of one autoimmune 
disease to another, and that more than one autoimmune disease 
may coexist in a single patient or in the same family.4,5,6 We 
did not fi nd the same case in her family.
Autoimmune thyroid disease occurs in 5–10% of patients 
with myasthenia gravis. It also seems as if AITD is found in 
excess in patients with SLE and secondary Sjögren’s syndrome, 
as well in SLE-unaffected relatives with a diagnosis of primary 
Sjögren’s syndrome.4,9,10,11
The diagnosis of SLE with vasculitis was based on the 
ACR criteria for SLE. Our patient fulfi lled 7 of 11 criteria, 
i.e. photosensitivity, oral ulcers, nonerosive arthritis, renal 
disorder, neuropsychiatric involvement (abnormal EEG), 
immunologic disorder (positive anti-dsDNA), and positive 
ANA (positive anti–Scl-70, anti–Rib-P protein, anti–SS-A, 
and anti–SS-B, with negative anti-mRNP). She also had SLE-
related vasculitis (confi rmed by skin biopsy) and nephritis 
lupus class I (confi rmed by renal biopsy).
Systemic lupus erythematosus is the most diverse of the 
autoimmune diseases, characterized by a wide range of clinical 
features and the production of multiple autoantibodies. The 
diagnosis is based on the clinical features and the presence of 
a wide variety of autoantibodies, most of which are directed to 
double-stranded DNA, nuclear antigens, ribonucleoproteins, 
and cell surface antigens. The treatment includes the use of 
antimalarial agents to corticosteroids and/or immunosuppressive 
agents. The primary pathological fi ndings are those of 
infl ammation, vasculitis, immune complex deposition and 
vasculopathy. The course of the disease is characterized by 
periods of fl ares and remission.  The incidence of SLE varies 
from 2 to 7.6 cases per 100,000 individuals per year; the 
highest prevalence is in Afro-Carribeans, followed by Asians. 
The sex ratio is 9:1 in favour of females with the disease 
onset between the ages of 15-55. The laboratory hallmark of 
the disease is the presence of ANA, appearing in more than 
95% of individuals with lupus. The most common pattern is a 
diffuse or homogeneous nuclear staining. Anti-DNA and anti-
Sm antibodies are rarely seen in other conditions and have 
therefore high specifi city for SLE.4,9,10
The diagnosis of SSc with pulmonary hypertension and 
Raynaud’s phenomenon-related gangrene on fi nger II, III, and 
IV of the left hand was supported by laboratory fi ndings, i.e. 
positive ANA with positive anti–SS-A, anti–SS-B, and anti–
Scl-70 on ANA profi le; hypercoagulable state, arterial stenosis 
of the left hand in angiography, and ABI of 0.84/0.91.
Systemic sclerosis is a chronic disease of unknown etiology, 
and its classifi cation as a systemic autoimmune rheumatic 
disease is supported by clinical and experimental observations 
that include the presence of autoantibodies and autoreactive 
T cells. Systemic sclerosis is a connective tissue disorder 
characterized by endothelial dysfunction, fi brosis, and the 
production of autoantibodies. Although some autoantibodies 
are specifi c markers for the disease, there has not been 
widespread adoption of them as specifi c classifi cation criteria. 
Excessive collagen deposition results in skin thickening and 
changes in internal organs that include the lung, vasculature, 
gastrointestinal tract, and kidney. Endothelial damage leading 
to vascular dysfunction manifests as Raynaud’s phenomenon, 
digital ulceration and gangrene, pulmonary arterial 
hypertension, and renal vascular damage. Systemic sclerosis 
is usually subclassifi ed as limited or diffuse depending on the 
extent of skin involvement. The distinction between limited 
and diffuse SSc varies, but most authors would concur that 
patients with truncal and acral involvement have diffuse 
disease, whereas changes of distal to the metacarpophalangeal 
and metatarsophalangeal joints are consistent with limited 
disease.  There is continuing debate over the degree of acral 
involvement that constitutes limited versus diffuse disease. 
Typically, patients with limited SSc have a more insidious 
disease onset, and they describe Raynaud’s phenomenon for 
some years prior to the onset of sclerodactyly. In contrast, in 
those with diffuse SSc the onset of Raynaud’s phenomenon 
and the disease course is more acute, with most internal 
organ involvement occurring within 5 years.4,8,9 Our patient 
typically had diffuse SSc, based on the truncal and acral skin 
involvement, pulmonary arterial hypertension, and Raynaud’s 
phenomenon-related digital gangrene.
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CONCLUSIONS
The diagnosis of MAS depends on the physician’s accuracy 
and the age of onset of the fi rst autoimmune disease. Our 
patient presented the symptoms of AITD (Graves’ disease) and 
systemic autoimmune disease (SLE and SSc). The diagnosis 
of one disease could only be achieved when it was suspected 
because most of the symptoms related to pulmonary artery 
hypertension, skin involvement, and vasculitis might be hidden 
by the symptoms of other disease.  The confi rmation will be 
made only by appropriate tests (i.e. abnormal immunology 
tests, abnormal arteriography, the presence of TRAb, or 
confi rming skin and renal biopsy).  Each individual disease 
included in the MAS group should be considered and treated 
accordingly.4,9,10,11
The presence of one autoimmune disease should alert one to 
watch for another one. The occurrence of multiple autoimmune 
phenomena in this case indicates the need for continued 
surveillance for the development of new autoimmune disease 
in predisposed patients.
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